Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $88.1667.

A number of research firms have issued reports on ARWR. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Sanford C. Bernstein raised their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Stifel Nicolaus began coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $98.00 target price for the company. Chardan Capital restated a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 30th. Finally, Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th.

Insider Activity

In other news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director owned 52,012 shares in the company, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,065 shares of company stock valued at $1,912,662 in the last quarter. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Carolina Wealth Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the period. CWM LLC increased its holdings in Arrowhead Pharmaceuticals by 1.4% during the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock worth $820,000 after purchasing an additional 168 shares during the period. First Horizon Corp increased its holdings in Arrowhead Pharmaceuticals by 36.2% during the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 174 shares during the period. PNC Financial Services Group Inc. raised its position in Arrowhead Pharmaceuticals by 1.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares in the last quarter. Finally, Optiver Holding B.V. raised its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 3.0%

Arrowhead Pharmaceuticals stock opened at $71.91 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The business’s 50-day simple moving average is $77.86 and its two-hundred day simple moving average is $69.43. The company has a market cap of $10.13 billion, a PE ratio of -33.45 and a beta of 1.26. Arrowhead Pharmaceuticals has a fifty-two week low of $14.30 and a fifty-two week high of $87.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period last year, the business posted $2.75 earnings per share. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. Equities analysts anticipate that Arrowhead Pharmaceuticals will post -3 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.